Несмотря на большие усилия, предпринимаемые для эффективного контроля артериальной гипертонии, достичь целевых значений артериального давления (АД) удается у меньшинства больных. Одним из новых представителей блокаторов рецепторов ангиотензина II 1-го типа (БРА), обладающих стабильным антигипертензивным эффектом, является азилсартана медоксомил. Антигипертензивный эффект азилсартана превосходит действие некоторых других БРА, поэтому расширяются возможности его применения в виде монотерапии. У больных non-dipper с нарушениями циркадного ритма АД азилсартан может быть препаратом выбора. Ключевые слова: артериальная гипертония, лечение гипертонии, азилсартан, Эдарби.
________________________________________________
Despite the great efforts made to effectively control hypertension, achieving target values of blood pressure (BP) can possible be in a minority of patients. One of the new representatives of the angiotensin II receptor blockers type 1 (ARBs), that has stable antihypertensive effect is azilsartan medoxomil. The antihypertensive effect of azilsartan is superior to some other ARBs, thus expanding the possibility of its use as monotherapy. In patients with non-dipper circadian rhythm of blood pressure azilsartan may be the drug of choice. Key words: arterial hypertension, treatment of hypertension, azilsartan, Edarbi.
1. Wolff-Maier K, Cooper RS, Banegas JR et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada and the United States. JAMA 2003; 289 (18): 2363–9.
2. Whitworth JA and World Health Organization, International Society of Hypertension Writing Group. World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21 (11): 1983–92.
3. Grassi G, Cifkova R, Laurent S et al. Blood pressure control and cardiovascular risk profile in hypertensive patients from central and eastern European countries: results of the BP-CARE study. Eur Heart J 2011; 32: 218–25.
4. Kotsevaa K, Wooda D, De Backerb G et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009; 16 (2): 121–37.
5. Graettinger WF2003 Systemic Hypertension. In: Crawford MH (eds). Current Diagnosis and Treatment in Cardiology 2nd edn. MacGraw-Hill Professional: New York, NY, USA; p. 167–78.
6. Appel GB, Appel AS. Angiotensin II receptor antagonists: role in hypertension, cardiovascular disease, and renoprotection. Prog Cardiovasc Dis 2004; 47 (2): 105–15.
7. Messerli FH, Weber MA, Brunner HR. Angiotensin II receptor inhibition, a new therapeutic principle. Arch Intern Med 1996; 156 (17): 1957–65.
8. Perry CM. Azilsartan medoxomil: a review of its use in hypertension. Clin Drug Investig 2012; 32 (9): 621–39.
9. Ojima M, Igata H, Tanaka M et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther 2011; 336 (3): 801–8.
10. Bönner G, Bakris GL, Sica D et al. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. J Hum Hypertens 2013; 27 (8): 479–86.
11. Sica D, White WB, Weber MA et al. Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure Monitoring. J Clin Hypertens 2011; 13: 467–72.
12. White WB, Weber MA, Sica D et al. Effects of the Angiotensin Receptor Blocker Azilsartan Medoxomil Versus Olmesartan and Valsartan on Ambulatory and Clinic Blood Pressure in Patients With Stages 1 and 2 Hypertension. Hypertension 2011; 57: 413–20.
13. Metoki H, Ohkubo T, Kikuya M et al. Prognostic significance for stroke of a morning pressor surge and a nocturnal blood pressure decline: The Ohasama study. Hypertension 2006; 47: 149–54.
14. Kikuya M, Ohkubo T, Asayama K et al. Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality: The Ohasama study. Hypertension 2005; 45: 240–5.
15. Hoshide S, Kario K, Hoshide Y et al. Associations between nondipping of nocturnal blood pressure decrease and cardiovascular target organ damage in strictly selected community-dwelling normotensives. Am J Hypertens 2003; 16: 434–8.
16. Ohkubo T, Imai Y, Tsuji I et al. Relation between nocturnal decline in blood pressure and mortality. The Ohasama Study. Am J Hypertens 1997; 10: 1201–7.
17. Kario K, Matsuno T, Kobayashi H et al. Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients. Advanced silent cerebrovascular damage in extreme dippers. Hypertension 1996; 27: 130–5.
18. Kario K, Pickering TG, Matsuo T et al. Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. Hypertension 2001; 38: 852–7.
19. Ohkubo T, Hozawa A, Yamaguchi J et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: The Ohasama study. J Hypertens 2002; 20: 2183–9.
20. Rakugi H, Kario К, Enya К et al. Effect of azilsartan versus candesartan on nocturnal blood pressure variation in Japanese patients with essential hypertension. Blood Press 2013; 22 (S1): 22–8.
21. Uzu T, Kimura G. Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation 1999; 100: 1635–8.
22. Sherwood A, Steffen PR, Blumenthal JA et al. Night-time blood pressure dipping: The role of the sympathetic nervous system. Am J Hypertens 2002; 15: 111–8.
23. Grassi G, Seravalle G, Quarti-Trevano F et al. Adrenergic, metabolic, and reflex abnormalities in reverse and extreme dipper hypertensives. Hypertension 2008; 52: 925–31.
24. Kario K, Schwartz JE, Pickering TG. Changes of nocturnal blood pressure dipping status in hypertensives by night-time dosing of α-adrenergic blocker, doxazosin: Results from the HALT study. Hypertension 2000; 35: 787–94.
25. Anan F, Takahashi N, Ooie T et al. Role of insulin resistance in nondipper essential hypertensive patients. Hypertens Res 2003; 26: 669–76.
26. Della Mea P, Lupia M, Bandolin V et al. Adiponectin, insulin resistance, and left ventricular structure in dipper and nondipper essential hypertensive patients. Am J Hypertens 2005; 18: 30–5.
27. Burnier M, Zanchi A. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens 2006; 24 (1): 11–25.
28. Sodhi CP, Kanwar YS, Sahai A. Hypoxia and high glucose upregulate AT1 receptor expression and potentiate ANG II-induced proliferation in VSM cells. Am J Physiol Heart Circ Physiol 2003; 284 (3): H846–H852.
29. Arun KH, Kaul CL, Ramarao P. AT1 receptors and L-type calcium channels: functional coupling in supersensitivity to angiotensin II in diabetic rats. Cardiovasc Res 2005; 65 (2): 374–86.
30. Sueta D, Kataoka К, Koibuchi N et al. Novel Mechanism for Disrupted Circadian Blood Pressure Rhythm in a Rat Model of Metabolic Syndrome – The Critical Role of Angiotensin II. Hypertension 2013; 2: e000035.
Авторы
И.И.Чукаева, Ф.Д.Ахматова
ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава России, Москва